Role of endolysosome function in iron metabolism and brain carcinogenesis

Seminars in Cancer Biology, Journal Year: 2021, Volume and Issue: 76, P. 74 - 85

Published: June 15, 2021

Language: Английский

---

Quantitative analysis of favipiravir and hydroxychloroquine as FDA‐approved drugs for treatment of COVID‐19 using synchronous spectrofluorimetry: application to pharmaceutical formulations and biological fluids

Luminescence, Journal Year: 2022, Volume and Issue: 37(6), P. 953 - 964

Published: March 28, 2022

Coronavirus disease 2019 (COVID-19) is a contagious viral infection caused by coronavirus 2 (SARS-CoV-2) that causes severe acute respiratory syndrome. It has ravaged several countries and burdened many healthcare systems. As the process of authorizing novel treatment for human use extensive involves multiple phases to obtain safety information identify potential concerns. Therefore, fastest easiest choice was United States Food Drug Administration (US FDA)-approved drugs such as favipiravir hydroxychloroquine. For simultaneous estimation both medications, simple synchronous spectrofluorimetric approach established in which were measured at 372 323 nm, respectively presence each other without interference Δλ 60 nm. The effect various experimental conditions on fluorescence intensities thoroughly investigated optimized. maximum obtained pH 5.4 using acetate buffer (0.2 M, 0.5 ml) ethanol diluent. Excellent linearity ranges 1.0-18.0 ng/ml 10.0-120.0 hydroxychloroquine, respectively. exhibited high sensitivity with detection limits down 0.25 1.52 quantitation 0.77 4.62 ng/ml, Spiking plasma samples studied yielded % recoveries, allowing significant bioanalytical application. Moreover, method validated according International Conference Harmonization guidelines further applied commercial pharmaceutical preparations good results.

Language: Английский

---

Structural growth of zinc oxide nanograins on carbon cloth as flexible electrochemical platform for hydroxychloroquine detection

Chemosphere, Journal Year: 2022, Volume and Issue: 312, P. 137186 - 137186

Published: Nov. 8, 2022

Language: Английский

---

Drugs for COVID-19: An Update

Molecules, Journal Year: 2022, Volume and Issue: 27(23), P. 8562 - 8562

Published: Dec. 5, 2022

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was the seventh known human coronavirus, and it identified in Wuhan, Hubei province, China, 2020. It caused highly contagious disease called 2019 (COVID-19), declared a global pandemic by World Health Organization (WHO) on 11 March A great number of studies search new therapies vaccines have been carried out these three long years, producing series successes; however, need for more effective vaccines, other solutions is still being pursued. This review represents tracking shot current pharmacological used treatment COVID-19.

Language: Английский

---

Solar Photocatalysis for the Decontamination Of Water from Emerging Pharmaceutical Pollutant Chloroquine Using Nano ZnO as the Catalyst

Water Air & Soil Pollution, Journal Year: 2023, Volume and Issue: 234(3)

Published: Feb. 17, 2023

Language: Английский

---

Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update

Clinical Pathology, Journal Year: 2024, Volume and Issue: 17

Published: Jan. 1, 2024

The COVID-19 pandemic-led worldwide healthcare crisis necessitates prompt societal, ecological, and medical efforts to stop or reduce the rising number of fatalities. Numerous mRNA based vaccines for viral vectors have been licensed use in emergencies which showed 90% 95% efficacy preventing SARS-CoV-2 infection. However, safety issues, vaccine reluctance, skepticism remain major concerns making mass vaccination a successful approach treat COVID-19. Hence, alternative therapeutics is needed eradicating global burden from developed low-resource countries. Repurposing current medications drug candidates could be more viable option treating as these therapies previously passed significant checkpoints development patient care. Besides vaccines, this review focused on potential usage therapeutic agents including antiviral, antiparasitic, antibacterial drugs, protease inhibitors, neuraminidase monoclonal antibodies that are currently undergoing preclinical clinical investigations assess their effectiveness treatment Among repurposed remdesivir considered most promising agent, while favipiravir, molnupiravir, paxlovid, lopinavir/ritonavir exhibited improved effects terms elimination viruses. outcomes with oseltamivir, umifenovir, disulfiram, teicoplanin, ivermectin were not significant. It noteworthy combining multiple drugs therapy showcases impressive managing individuals Tocilizumab presently employed patients who exhibit COVID-19-related pneumonia. antiviral such galidesivir, griffithsin, thapsigargin under trials severe symptoms. Supportive may involve corticosteroids, convalescent plasma, stem cells, pooled antibodies, vitamins, natural substances. This study provides an updated progress crucial guide inventing novel interventions against

Language: Английский

---

Systematic Review of the Common Pathophysiological Mechanisms in COVID-19 and Neurodegeneration: The Role of Bioactive Compounds and Natural Antioxidants

Cells, Journal Year: 2022, Volume and Issue: 11(8), P. 1298 - 1298

Published: April 11, 2022

The novel coronavirus (2019-nCoVCOVID-19) belongs to the Beta family, which contains MERS-CoV (Middle East respiratory syndrome coronavirus) and SARS-CoV (severe acute coronavirus). SARS-CoV-2 activates innate immune system, thereby activating inflammatory mechanism, causing release of cytokines. Moreover, it has been suggested that COVID-19 may penetrate central nervous cytokines in brains, inducing neuroinflammation neurodegeneration. Several links connect with Alzheimer’s disease (AD), such as elevated oxidative stress, uncontrolled cytokines, mitochondrial apoptosis. There are severe concerns excessive cell activation aggravate neurodegeneration amyloid-beta pathology AD. Here, we have collected evidence, showing between two diseases. focus made collect information on inflammation, its contributors, shared therapeutic targets. Furthermore, given future perspectives, research gaps, overlapping pathological bases Lastly, short touch drugs equally shown rescuing effects against both Although there is limited available regarding exact neuroinflammation, insight into contributors Based features targets, hypothesize system induce neurological disorders by triggering stress neuroinflammation.

Language: Английский

---

Multifunctional pH-responsive nanogel for malaria and cancer treatment: Hitting two targets with one arrow

Journal of Drug Delivery Science and Technology, Journal Year: 2022, Volume and Issue: 76, P. 103740 - 103740

Published: Aug. 26, 2022

Language: Английский

---

Epstein–Barr virus-acquired immunodeficiency in myalgic encephalomyelitis—Is it present in long COVID?

Journal of Translational Medicine, Journal Year: 2023, Volume and Issue: 21(1)

Published: Sept. 17, 2023

Abstract Both myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) and long COVID (LC) are characterized by similar immunological alterations, persistence of viral infection, autoimmunity, inflammatory state, reactivation, hypocortisolism, microclot formation. They also present with symptoms such as asthenia, exercise intolerance, sleep disorders, cognitive dysfunction, neurological gastrointestinal complaints. In addition, both pathologies Epstein–Barr virus (EBV) indicating the possibility this being link between pathologies. Therefore, we propose that latency recurrent EBV reactivation could generate an acquired immunodeficiency in three steps: first, develops individuals “weak” HLA-II haplotypes, which prevents control I cells. Second, ectopic lymphoid structures form different tissues (including CNS), promoting responses further impairment cell-mediated immunity. Finally, immune exhaustion occurs due to exposure antigens, consolidation disease. case LC, prior first step, there is previous SARS-CoV-2 infection haplotypes against and/or EBV.

Language: Английский

---

Understanding the Molecular Biology of SARS-CoV-2 and the COVID-19 Pandemic: A Review

Infection and Drug Resistance, Journal Year: 2021, Volume and Issue: Volume 14, P. 2259 - 2268

Published: June 1, 2021

Abstract: Coronaviruses are named after the crown-like spike proteins on their surface. In 21st century, three coronaviruses, namely severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV, and Middle East related (MERS-CoV), have emerged in human population, presumably evolving from pathogens infecting other animals. enveloped viruses responsible for 15– 30% of atypical pneumonia cases humans worldwide. The current disease 2019 (COVID-19) pandemic is caused by newest SARS virus, SARS-CoV-2, an enveloped, positive-sense, single-stranded RNA betacoronavirus family Coronaviridae. As April 2021, World Health Organization has reported more than 3 million deaths COVID-19 140 people been infected with thereby making it worst all time. Here, I review understanding molecular biology coronaviruses host interactions, bringing together knowledge infection process to aid development therapeutic drugs and/or vaccines against SARS-CoV-2. also briefly overview situation available treatments, vaccinations, emerging strains. Keywords: ACE2, coronavirus, protein, mechanism, vaccine

Language: Английский

---